ライフサイエンスコーパス: NAAT

1 NAAT identified 13 (0.1%) of the 12,338 HIV antibody-neg

2 NAAT is significantly (P<0.0001) more sensitive than cel

3 NAATs are both rapid and sensitive.

4 NAATs perform well for detection of chlamydia and gonorr

5 NAATs were performed on FCU, urethral, cervical, self- a

6 Follow-up testing of 12 of the 13 NAAT-positive individuals at 6 months demonstrated 12 se

7 We assumed a NAAT cost of US$25, NAAT specificity of 99.6%, NAAT sensitivity of 100% for

8 and 1 in-house HIV test (6 EIA, 4 RT, and 3 NAAT) on panels of plasma samples from HIV-infected (n =

9 AT cost of US$25, NAAT specificity of 99.6%, NAAT sensitivity of 100% for infants infected in pregnan

10 We assumed a NAAT cost of US$25, NAAT specificity of 99.6%, NAAT sens

11 on, who has been a consistent advocate for a NAAT-only approach for CDI diagnosis, will discuss the v

12 r CDI diagnosis, will discuss the value of a NAAT-only approach, while Christopher Polage of the Univ

13 Until a NAAT for T. vaginalis is commercially available, a stepw

14 We found that the LCx, ProbeTec, and AC2 NAATs are highly sensitive and specific methods for the

15 st frequently cited reasons for not adopting NAAT.

16 All NAATs then commercially available (October 1996 to Octob

17 4%), but culture was less sensitive than all NAATs (67% to 73%).

18 onfirmed as true positives by an alternative NAAT.

19 y, culture, drug susceptibility testing, and NAAT.

20 For FCU samples from men, any NAAT can be used for confirmation.

21 idence regarding this commercially available NAAT for testing of specimens after mailing.

22 will update us on the commercially available NAAT systems and explain what their role should be in th

23 performance of three commercially available NAATs (Becton-Dickinson ProbeTec SDA, Gen-Probe Aptima C

24 Currently available NAATs are more sensitive for the detection of chlamydial

25 In conclusion, currently available NAATs are more sensitive than culture for the detection

26 -based NAAT (Aptima Combo 2) and a DNA-based NAAT (Cobas 4800).

27 r RNA-based NAAT and 1-15 days for DNA-based NAAT.

28 howed 100% concordance with laboratory-based NAAT.

29 cutive days, and analyzed using an RNA-based NAAT (Aptima Combo 2) and a DNA-based NAAT (Cobas 4800).

30 days, with a range of 1-7 days for RNA-based NAAT and 1-15 days for DNA-based NAAT.

31 ositive with an alternative target TMA-based NAAT, APTIMA C. trachomatis, suggesting that they may ha

32 therapy, when using modern RNA- or DNA-based NAATs, respectively.

33 earance when using modern RNA- and DNA-based NAATs.

34 improved sensitivities compared to DNA-based NAATs; and the progression of scarring has now been char

35 on of Altona with a laboratory-developed BKV NAAT assay in IU/ml versus copies/ml using Passing-Bablo

36 ble to the primary standard to harmonize BKV NAAT results, we anticipate improved interassay comparis

37 Increased detection by NAAT of cervical C. trachomatis over PACE2 was highest a

38 , respectively, were detected exclusively by NAAT.

39 ity of infection than total load measured by NAAT.

40 e percent and 22% of the samples positive by NAAT and TC, respectively, were negative by the toxin B

41 -positive samples, 24 (96%) were positive by NAAT, whereas 25 of 25 true-negative samples (100%) show

42 tive by toxin EIA and 98% tested positive by NAAT.

43 tive by toxin EIA and 98% tested positive by NAAT.

44 (1.5%) of 66 control samples was positive by NAAT.

45 stool specimens already tested routinely by NAAT.

46 = 5) were tested for C. trachomatis rRNA by NAAT.

47 ion of C. trachomatis in ocular specimens by NAAT was verified for laboratory diagnosis.

48 nosing chlamydial genital tract infection by NAATs.

49 samples that were C. trachomatis negative by NAATs, 33/45 and 197/212 were correctly identified by th

50 1,000 self-collected vaginal swabs tested by NAATs, the sensitivities for C. trachomatis and N. gonor

51 The prevalence of C. trachomatis by NAATs was 17.5%.

52 clearly visualizing the effects of changing NAAT-based infected-patient gold standards and should be

53 ens were tested using culture and commercial NAATs employing transcription-mediated amplification (TM

54 ich were available by using other commercial NAATs.

55 If four comparator NAAT results were used, the any-three-positive-of-four-r

56 CSF of immunocompetent adults for viral CSF NAAT assays would increase clinical specificity and pres

57 phone and droplet magnetofluidics to deliver NAAT in a portable and accessible format.

58 AC2, SDA, or PCR were retested by different NAATs (SDA, PCR, AC2, and Aptima Neisseria gonorrhoeae a

59 C2; Digene Corp.) were retested by different NAATs (SDA, PCR, AC2, and the APTIMA assay for C. tracho

60 clear how many test results run by different NAATs and what combinations of specimens comprise the be

61 positive results were confirmed by different NAATs, but that some NAATs cannot be used to confirm oth

62 describing a direct comparison of different NAATs have been limited.

63 of 1,412 women and tested by three different NAATs.

64 urine comparator results with two different NAATs, The effect of changing the infected-patient gold

65 C2 results were confirmed by using different NAATs on the original specimen.

66 prospectively by toxin EIA, by C. difficile NAAT, and with a reference standard toxigenic culture.

67 T (ACT) and APTIMA GC (AGC) are two discrete NAATs for C. trachomatis and N. gonorrhoeae detection th

68 , cytomegalovirus (CMV), or enterovirus (EV) NAAT with CSF samples between 2008 and 2013 were include

69 Few NAAT studies reported adult-specific data, and none eval

70 or DIAs, and 91.6% (CrI, 84.9% to 95.9%) for NAATs.

71 study, we evaluated the performance of four NAATs, qPCR, dPCR, real-time quantitative loop mediated

72 nd then examined the effects of implementing NAAT testing.

73 or AHI case detection compared to individual NAAT.

74 s the role of future iterations of influenza NAATs and whether this testing would be available in a c

75 Introducing NAAT testing initially increases diagnoses, by finding a

76 evidence for the timing of TOC using modern NAATs is limited, we performed a prospective cohort stud

77 Previously, our group described a multiplex NAAT for the detection of dengue virus, Leptospira, and

78 such as S. pyogenes, or commercial multiplex NAATs for detection of a variety of pathogens in gastroi

79 om a large study of the performance of a new NAAT.

80 Now, there are numerous NAATs in the marketplace, and based on recent proficienc

81 Agreement of NAAT results between VS and cervical swabs or FCU was ca

82 These findings support expanded use of NAAT for screening and diagnosis of C. trachomatis in di

83 with mild CDI and support the routine use of NAAT for the diagnosis of CDI.

84 ncluded (130 of RIDTs, 19 of DIAs, and 13 of NAATs).

85 lyzed data from a head-to-head comparison of NAATs on female FCU specimens and found that the volume

86 detection of TV by routine implementation of NAATs should result in better control of this common, tr

87 this series, where she advocated the use of NAATs for influenza diagnosis.

88 ted diagnostic testing with increased use of NAATs when appropriate; routine follow-up visits within

89 erature conditions may impact the utility of NAATs in some settings and screening programs.

90 carriage, the diagnostic predictive value of NAATs is limited when used in patients with a low probab

91 specimen sensitivity and specificity for one NAAT method were created by varying the number and combi

92 whereas 31.5% were positive by at least one NAAT.

93 t some NAATs cannot be used to confirm other NAATs.

94 confirmation of positive results from other NAATs, such as AC2 and LCx.

95 used to confirm positive results from other NAATs.

96 For CSA patients, NAATs are considered to be acceptable for identification

97 Pooled NAAT (or group testing) can improve efficiency and test

98 eae patient was defined as > or = 2 positive NAAT results.

99 on have recommended confirmation of positive NAAT results in low-prevalence populations.

100 The average duration of positive NAAT results was 6.8 weeks (range 2-16).

101 more positive results; >90% of all positive NAATs could be confirmed.

102 With >90% of all GC-positive NAATs being confirmed, our results show that confirmator

103 itive result was defined as any two positive NAATs.

104 sensitive tests for T. vaginalis, preferably NAATs, if microscopy is negative.

105 Now S. pyogenes NAATs are being used with increasing frequency.

106 Patel of the Mayo Clinic, where S. pyogenes NAATs have been used for well over a decade with great s

107 Novel DIAs and rapid NAATs had markedly higher sensitivities for influenza A

108 tage points, except for influenza A by rapid NAATs (2.7 percentage points).

109 f enterovirus in CSF either by two reference NAATs or by viral culture.

110 investigational/research use only (IUO/RUO) NAATs for the detection of C. difficile toxin genes, the

111 ive specimens were then retested by the same NAAT for confirmation.

112 iagnostic Systems) were retested by the same NAAT.

113 g results for retested samples from a second NAAT (Xpert C. difficile/Epi test; Cepheid, Sunnyvale, C

114 ion recommends that infants undergo a second NAAT to confirm any positive test result, but implementa

115 ith presumptive PTB in a low-burden setting, NAAT can reduce AII and is comparably sensitive, more sp

116 plification test (NAAT) results, or a single NAAT-positive result confirmed by an alternate amplifica

117 confirmed by different NAATs, but that some NAATs cannot be used to confirm other NAATs.

118 However, for all other specimen types, some NAATs cannot be used to confirm positive results from ot

119 We conclude that in Washington State, NAAT have been rapidly adopted in larger laboratories, b

120 In our study, NAATs improved the detection of infected women by 17 to

121 n of Trichomonas vaginalis by vaginal swabs; NAATs for detection of Neisseria gonorrhoeae and Chlamyd

122 that were negative by cytotoxicity assay/TC/NAAT, clinical cutoffs were set at 29.4 pg/ml (toxin A)

123 rming nucleic acid amplification techniques (NAATs) in digital format using limiting dilution provide

124 FDA-cleared nucleic acid amplification test (NAAT) but were negative for stx1 and stx2 following nucl

125 ion-cleared nucleic acid amplification test (NAAT) for the detection of Chlamydia trachomatis and Nei

126 assay is a nucleic acid amplification test (NAAT) for the detection of Mycobacterium tuberculosis co

127 rmance of a nucleic acid amplification test (NAAT) for the diagnosis of Mycobacterium tuberculosis ba

128 re positive nucleic acid amplification test (NAAT) results, or a single NAAT-positive result confirme

129 ])-positive nucleic acid amplification test (NAAT) results: (i) repeating the original test on the or

130 lture and a nucleic acid amplification test (NAAT) were used to detect T. vaginalis.

131 only 3 of 8 nucleic acid amplification test (NAAT)-based studies (P = .03).

132 eening, all nucleic acid amplification test (NAAT)-positive respiratory specimens should be universal

133 mpared to a nucleic acid amplification test (NAAT).

134 test, and a nucleic acid amplification test [NAAT]) were performed on vaginal swabs.

135 n of BKV nucleic acid amplification testing (NAAT) and enabling comparisons of biological measurement

136 ested by nucleic acid amplification testing (NAAT) and in cell cultures.

137 ecessary nucleic acid amplification testing (NAAT) for viral pathogens in cerebrospinal fluid (CSF) s

138 Nucleic acid amplification testing (NAAT) has become the preferred method to detect Chlamydi

139 Nucleic acid amplification testing (NAAT) is increasingly being adopted for diagnosis of Clo

140 Nucleic acid amplification testing (NAAT) is the preferred method to detect Chlamydia tracho

141 cost of nucleic acid amplification testing (NAAT) makes individual testing of at-risk individuals pr

142 ested by nucleic acid amplification testing (NAAT) to identify acute infections.

143 ture and nucleic acid amplification testing (NAAT) were completed weekly throughout the study.

144 However, nucleic acid amplification testing (NAAT) with the Xpert MTB/RIF assay (Xpert) may be more e

145 tions by nucleic acid amplification testing (NAAT), as they involve a less invasive collection method

146 ation of nucleic acid amplification testing (NAAT; Gen-Probe Aptima Combo 2 assay) for detection of C

147 [TC] and nucleic acid amplification testing [NAAT]) are confounded by asymptomatic colonization by to

148 doption of nucleic acid amplification tests (NAAT) for Clostridium difficile diagnosis and their impa

149 duction of nucleic acid amplification tests (NAAT), we surveyed laboratories in Washington State abou

150 T) and HIV nucleic acid amplification tests (NAAT).

151 performance of nucleic acid amplified tests (NAAT) for Chlamydia trachomatis at the cervix and in uri

152 Commercial nucleic acid amplification tests (NAATs) are becoming available, and their use in screenin

153 bacterium, nucleic acid amplification tests (NAATs) are necessary for its detection in patient specim

154 Nucleic acid amplification tests (NAATs) are quickly becoming the standard of care.

155 Nucleic acid amplification tests (NAATs) are reliable tools for the detection of toxigenic

156 s (EIA) to nucleic acid amplification tests (NAATs) as the primary diagnostic test for Clostridium di

157 Nucleic acid amplification tests (NAATs) can be used to define the infected-patient "gold

158 Because nucleic acid amplification tests (NAATs) do not distinguish Clostridium difficile infectio

159 itivity of nucleic acid amplification tests (NAATs) for Chlamydia trachomatis and Neisseria gonorrhoe

160 g positive nucleic acid amplification tests (NAATs) for Chlamydia trachomatis: (i) repeat the origina

161 ude use of nucleic acid amplification tests (NAATs) for detection of Trichomonas vaginalis by vaginal

162 d value of nucleic acid amplification tests (NAATs) for detection of TV in men and women at high risk

163 Nucleic acid amplification tests (NAATs) for enterovirus RNA in cerebrospinal fluid (CSF)

164 available nucleic acid amplification tests (NAATs) for influenza virus detection.

165 ization of nucleic acid amplification tests (NAATs) for near-patient applications is not the amplific

166 ulture and nucleic acid amplification tests (NAATs) for rectal chlamydial and gonococcal diagnosis.

167 Nucleic acid amplification tests (NAATs) for the detection of Chlamydia trachomatis are ro

168 A-approved nucleic acid amplification tests (NAATs) for the detection or confirmation of HIV-2 infect

169 ulture and nucleic acid amplification tests (NAATs) for the diagnosis of pharyngeal N. gonorrhoeae.

170 available nucleic acid amplification tests (NAATs) for trichomoniasis are accurate, quick and confir

171 ocessed by nucleic acid amplification tests (NAATs) has significantly increased the utilization of no

172 Recently, nucleic acid amplification tests (NAATs) have been approved for testing for the presence o

173 RNA-based nucleic acid amplification tests (NAATs) have demonstrated improved sensitivities compared

174 Nucleic acid amplification tests (NAATs) have frequently been the standard diagnostic appr

175 Nucleic acid amplification tests (NAATs) have revolutionized infectious disease diagnosis,

176 and rapid nucleic acid amplification tests (NAATs) in children and adults with suspected influenza.

177 o, CA) are nucleic acid amplification tests (NAATs) that detect Chlamydia trachomatis AC2 also detect

178 A)-cleared nucleic acid amplification tests (NAATs) to culture using 314 vaginal/rectal swabs after 1

179 The use of nucleic acid amplification tests (NAATs) to diagnose Neisseria gonorrhoeae infections comp

180 ificity of nucleic acid amplification tests (NAATs) used for early infant diagnosis (EID) of HIV infe

181 of malaria nucleic acid amplification tests (NAATs) using these specimen types.

182 ccus (GBS) nucleic acid amplification tests (NAATs) were compared to that of enriched culture for det

183 that time, nucleic acid amplification tests (NAATs) were just becoming commercially available, and th

184 e compared nucleic acid amplification tests (NAATs) with diagnostic tests other than those by culture

185 s, such as nucleic acid amplification tests (NAATs), to evaluate prepubertal children for N. gonorrho

186 o those of nucleic acid amplification tests (NAATs).

187 variety of nucleic acid amplification tests (NAATs).

188 sensitive nucleic acid amplification tests (NAATs).

189 cimen with nucleic acid amplification tests (NAATs).

190 with VS (93%) was as high as or higher than NAAT sensitivity with cervical swabs (91%) or FCU (80.6%

191 e is a body of literature that suggests that NAATs lack clinical specificity and thus inflate CDI rat

192 The NAAT shows promise, but modifications should focus on im

193 beneficial for public health programs if the NAAT manufacturers sought FDA clearance for this specime

194 The NAATs performed comparably and were more sensitive than

195 Discordant results between the NAATs were reevaluated using the Aptima CT or Aptima GC

196 Discordant results between the NAATs were repeated using the assays APTIMA CT or APTIMA

197 Specificities of the NAATs ranged from 95.6% to 98.5% (two-of-three standard)

198 Agreement of the NAATs with each other was high (97.1% to 98.4%), but cul

199 pecimens were tested simultaneously with the NAATs, following 18 to 24 h of Lim broth enrichment; 15%

200 All three NAATs were more sensitive (sensitivity, 90.9 to 100%) th

201 culture and greater than 95.5% for all three NAATs.

202 omatis and N. gonorrhoeae by using all three NAATs.

203 ere tested for C. trachomatis with the three NAATs, and a true-positive result was defined as any two

204 omatis detection in urine samples with three NAATs: the Abbott LCx (LCx), BD ProbeTec ET (ProbeTec),

205 o changing from toxin enzyme immunoassays to NAAT.

206 TV NAAT detected approximately one-third more infections am

207 ents (3821 women and 2514 men) received a TV NAAT on endocervical, urethral, or urine specimens.

208 ted Diseases (STD) Clinic and receiving a TV NAAT.

209 ive performance characteristics of these two NAATs were assessed with genital specimens from 284 wome

210 ve these reagents and release DNA in typical NAAT sample preparation methods.

211 irmatory testing remained cost-saving unless NAAT cost exceeded US$400 or the HIV-uninfected status o

212 While no laboratory routinely used NAAT in 1995, ligase chain reaction (LCR) was used in 23

213 Laboratories using NAAT had stricter rejection policies and increased posit

214 th complete surveys, 51 (43%) reported using NAAT in 2011.

215 trachomatis and Neisseria gonorrhoeae using NAATs and bacterial vaginosis using Gram stains.

216 During this study, 1.3% (n = 140) of viral NAAT studies yielded positive results.

217 We show that the same principle applies when NAATs are used for confirmation.

218 The overall rates of agreement with NAAT results for the individual 16S rRNA and cryptic pla

219 ostatistical models of specimen pooling with NAAT for the identification of AHI cases; these models i

220 erves further evaluation and comparison with NAATs and may well offer an attractive alternative for d

221 Among culture-positive women, NAAT sensitivity with VS (93%) was as high as or higher